Retatrutide vs Tirzepatide vs Semaglutide: How the Three Compare on Weight Loss

You've seen the three names everywhere, usually with a bigger number attached to each one as you scroll. Semaglutide built the category. Tirzepatide beat it. Retatrutide posted a phase 2 number so large it made headlines. So the question almost everyone is quietly asking is simple: which one is actually best — and is "best" even the right way to think about it?

The honest answer is that these are three different molecules doing increasingly aggressive things to your metabolism, and the trial headlines compare different drugs, at different doses, over different timelines, in different populations. A clean "24 beats 22 beats 15" leaderboard is tidy and mostly wrong. The number that matters isn't the one from someone else's trial — it's the one your own body produces.

This post walks through what genuinely separates the three: how they work, what the best trials actually showed, where each stands with the FDA, the muscle-loss issue they all share, and — the part nobody sells you — how to read your own data once you're on one.

A note before we start: This is education, not medical advice. Many peptides discussed here are not FDA-approved, are sold as research chemicals, or are banned in competitive sport. Nothing here tells you to start, stop, or dose anything — talk to a licensed clinician for that. What Peplens helps with is reading your own data honestly once you're on a protocol.

The Mechanism: One Hormone, Two, or Three

The cleanest way to understand these three is to count receptors. Each generation adds one.

Semaglutide is a single agonist: it mimics GLP-1 (glucagon-like peptide-1), a gut hormone that slows stomach emptying, blunts appetite, and improves insulin response. One lever, pulled hard. This is the mechanism behind Ozempic and Wegovy.¹

Tirzepatide is a dual agonist: GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone, and combining the two appears to produce more appetite suppression and better metabolic effects than GLP-1 alone — which is why it's marketed as Mounjaro and Zepbound.²

Retatrutide is a triple agonist: GLP-1, GIP, and glucagon. The glucagon receptor is the new and interesting part. Glucagon, counterintuitively, can increase energy expenditure and promote fat utilization, so the theory is that retatrutide doesn't just suppress intake — it may also nudge the "burn" side of the equation.³ That third receptor is exactly why retatrutide's results look different, and also why its regulatory path is more uncertain.

You can read the full mechanism, dosing-stage, and status breakdowns in our encyclopedia: retatrutide, tirzepatide, and semaglutide.

The Numbers: What the Trials Actually Showed

Here is where it pays to be precise, because the internet is not.

Semaglutide — STEP 1. In the pivotal STEP 1 trial (1,961 adults with overweight or obesity, no diabetes), semaglutide 2.4 mg weekly produced a mean weight loss of about 14.9% over 68 weeks.⁴

Tirzepatide — SURMOUNT-1. In SURMOUNT-1 (2,539 adults), tirzepatide at the top 15 mg dose produced roughly 20.9% to 22.5% mean weight loss over 72 weeks, depending on the analysis method used.⁵ The honest framing is "low-to-mid 20s," not a single magic figure.

Retatrutide — phase 2. In the phase 2 trial published in the New England Journal of Medicine (338 adults), the 12 mg dose produced a mean weight reduction of 24.2% at 48 weeks — and notably, the curve hadn't fully flattened, suggesting more could come with a longer trial.⁶ Early phase 3 TRIUMPH readouts have continued to look strong.⁷

Two cautions before you treat that as a ranking. First, the best head-to-head data come from SURMOUNT-5, which directly compared tirzepatide and semaglutide in the same trial: tirzepatide produced about 20.2% weight loss versus 13.7% for semaglutide at 72 weeks.⁸ That's a real, like-for-like edge for tirzepatide. Second, retatrutide has never been tested head-to-head against the other two — its 24% comes from a separate, shorter, smaller trial. Cross-trial comparison is suggestive, not proof.

So the fair summary is: tirzepatide reliably out-loses semaglutide in a direct comparison, and retatrutide looks like it may go further still — but that last claim is a phase-2 signal awaiting phase-3 confirmation, not a settled fact.

Approval Status: Two on Shelves, One Still Investigational

This is the most practically important difference and the one most often glossed over.

Semaglutide and tirzepatide are FDA-approved for chronic weight management (as Wegovy and Zepbound, respectively) and for type 2 diabetes (as Ozempic and Mounjaro). They are prescription medications with established manufacturing, labeling, and safety monitoring.

Retatrutide is not FDA-approved. As of mid-2026 it remains investigational, working through Eli Lilly's phase 3 TRIUMPH program, with a regulatory submission anticipated and a plausible approval window often projected for late 2027 into 2028 — though timelines slip and nothing is guaranteed.⁷⁹ Its novel glucagon component means the agency is reviewing a mechanism it hasn't approved before, which adds uncertainty.⁹

The compliance reality: any "retatrutide" available right now is being sold as a research chemical not intended for human use, outside the approval, manufacturing, and quality controls that govern the approved drugs. That is a materially different risk category, and it is a conversation for a licensed clinician — not a blog.

The Muscle-Loss Issue All Three Share

Here's the part the weight-loss headlines bury: a meaningful fraction of the weight you lose on any of these is lean mass, not fat. This isn't unique to one drug — it's a feature of rapid weight loss in general.

The DEXA substudy data are clarifying. In SURMOUNT-1, tirzepatide users lost weight that was roughly 75% fat mass and 25% lean mass — about a 34% lean-mass fraction by one published calculation.¹⁰ In STEP 1, semaglutide's lean-mass fraction ran higher, around 40-45% of total weight lost by comparable analysis.¹⁰ Across the board, expect somewhere between a quarter and nearly half of the scale drop to be lean tissue if you do nothing to defend it.

Whether that's "bad" is genuinely debated — some of it is normal, adaptive remodeling, since a smaller body needs less supporting tissue.¹¹ But the levers that protect lean mass are the same regardless of which molecule you're on: enough protein, resistance training, and not losing weight faster than necessary. We go deep on this in how to keep muscle on GLP-1. The key point for this comparison: the drug determines how much total weight comes off; your behavior largely determines what that weight is made of.

How to Tell Which One Is Working for YOU

Cross-trial averages describe populations. They say almost nothing about the single person who matters to you. Response varies widely — plenty of people on "weaker" semaglutide out-lose the trial average for "stronger" tirzepatide, and side-effect tolerance is intensely individual.

So judge your own protocol on your own data, not the leaderboard:

• Weight as a 7-day trend, never a single morning. Daily water swings dwarf weekly fat change; the rolling average is the signal.
• Body-fat % and lean mass, not just total weight. A flat scale with dropping body fat and held lean mass is a win the scale alone can't see. Track it with InBody or DEXA on a consistent cadence.
• Recovery markers (resting HR, HRV). These tell you the cost — whether the deficit and the drug are taxing your system harder than you're recovering from.
• A relevant lab or two (e.g., HbA1c, lipids) so you can see metabolic benefit, not only weight.

This is exactly the problem Peplens is built for: it pulls your WHOOP, smart scale, InBody, and lab results into one screen and runs an AI coach over the combined picture, so "is this working?" becomes a reading instead of a guess. Here's how it works. For the full method on interpreting a protocol honestly, see how to tell if your peptide protocol is working, and browse the peptide encyclopedia for the compound-by-compound details.

The Peplens Take

Tirzepatide beats semaglutide in the only direct comparison we have, and retatrutide's triple-agonist mechanism produced the largest phase 2 number yet — but it's still investigational, still sold as a research chemical, and still unproven head-to-head. Ranking them off mismatched trial averages makes for a clean headline and a misleading decision.

What's not ambiguous: whichever you and your clinician land on, the result that matters is the one your own body produces. Track the 7-day weight trend, your body composition, your recovery, and a lab or two together — that's how you find out whether your protocol is working, instead of trusting a number from someone else's trial.

Medical Disclaimer

This article is for educational and informational purposes only and is not medical advice. Always consult a qualified clinician before starting, stopping, or changing any peptide, medication, supplement, diet, or exercise program. Many peptides referenced here are not FDA-approved, are sold as research chemicals not for human consumption, and/or are prohibited in sport under WADA rules. Peplens is a personal data-tracking and education tool, not a medical device or healthcare provider. Individual results vary.